A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women

European Journal of Cancer

Volumn 42, Issue 8, 2006, Pages 1129-1134

  Gal, Inabr ^a   Kimmel, Gad ^c   Gershoni Baruch, Ruth ^d   Papa, Moshe Z ^b   Dagan, Efrat ^d   Shamir, Ron ^c   Friedman, Eitan ^a  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Association study; BRCA1; BRCA2; Haplotype; High risk population; Odds ratio; RAD51; Relative risk

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RAD51 PROTEIN;

ADULT; ALGORITHM; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; ETHNOLOGY; FAMILIAL CANCER; FEMALE; GENE CONSTRUCT; GENE FREQUENCY; GENETIC RISK; GENOMICS; GENOTYPE; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENOTYPE; HAPLOTYPES; HETEROZYGOTE; HUMANS; JEWS; MIDDLE AGED; MUTATION; ODDS RATIO; RAD51 RECOMBINASE; RISK FACTORS;

EID: 33646424344     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.09.035     Document Type: Article

References (33)

1. Narod S.A. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2 (2002) 113-123
2. Houlston R.S., and Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene 23 (2004) 6471-6476
3. Tonin P., Weber B., Offit K., et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352 9137 (1998) 1337-1339
4. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 in a population based series of breast cancer cases. Br J Cancer 2000;83:1301-8.
5. King M.C., Marks J.H., and Mandel J.B. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
6. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med 336 (1997) 1401-1408
7. Chen J.J., Silver D., Cantor S., Livingston D.M., and Scully R. BRCA1, BRCA2, and RAD51 operate in a common DNA damage response pathway. Cancer Res 59 Suppl. (1999) 1752s-1756s
8. Kato M., Yano K., Matsuo F., et al. Identification of Rad51 alteration in patients with bilateral breast cancer. J Hum Genet 45 (2000) 133-137
9. Kadouri L., Kote-Jarai Z., Hubert A., et al. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer 90 (2004) 2002-2005
10. Levy-Lahad E., Lahad A., Eisenberg S., et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98 (2001) 3232-3236
11. Wang W.W., Spurdle A.B., Kolachana P., et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 10 (2001) 955-960
12. Maacke H., Jost K., Opitz S., et al. DNA repair and recombination factor RAD51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19 (2000) 2791-2795
13. Maacke H., Opitz S., Jost K., et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 88 (2000) 907-913
14. Yoshikawa K., Ogawa T., Baer R., et al. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int J Cancer 88 (2000) 28-36
15. Yanagisawa T., Urade M., Yamamoto Y., and Furuyama J. Increased expression of human DNA repair genes, XRCC1, XRCC3 and RAD51, in radioresistant human KB carcinoma cell line N10. Oral Oncol 34 (1998) 524-528
16. Taki T., Ohnishi T., Yamamoto A., et al. Antisense inhibition of the Rad51 enhances radiosensitivity. Biochem Biophys Res Commun 223 (1996) 434-438
17. Collis S.G., Tighe A., Scott S.D., Roberts S.A., Hendry J.H., and Margison G.P. Ribozyme-mediated RAD51 downregulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 29 (2001) 1534-1538
18. Blasiak J., Przybylowska K., Czechowska A., et al. Analysis of the G/C polymorphism in the 5′-untranslated region of the RAD51 gene in breast cancer. Acta Biochim Pol 50 (2003) 249-253
19. Bonnen P., Wang P.J., Figer A., Arbel S., Friedman E., and Nelson D. Complex SNP haplotype at BRCA1 shows potential association with breast cancer in Ashkenazi Jewish women: no evidence for association at ATM, BRCA2 and RAD51. Am J Hum Genet 69 #31 (2001) 181
20. Lynch H.T., Watson P., Tinley S., et al. An update on DNA-based BRCA1/BRCA2 genetic counselling in hereditary breast cancer. Cancer Genet Cytogenet 109 (1999) 91-98
21. Rohlfs E.M., Learning W.G., Friedman K.J., Couch F.J., Weber B.L., and Silverman L.M. Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43 (1997) 24-29
22. Shiri-Sverdlov R., Oefner P., Green L., et al. Mutational analysis of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum Mutat 16 (2000) 491-501
23. Ronaghi M. Pyrosequencing for SNP genotyping. Methods Mol Biol 212 (2003) 189-195
24. Kimmel G, Shamir R. GERBIL: Genotype resolution and block identification using likelihood. Proc Natl Acad Sci USA 2005;102:158-62.
25. Eskin E, Halperin E, Karp RM. Large scale reconstruction of haplotypes from genotype data. In: Proceedings of the seventh annual international conference on research in computational molecular biology. RECOMB 2003;104-13.
26. Greenspan G, Geiger D. Model-based inference of haplotype block variation. In: Proceedings of the seventh annual international conference on research in computational molecular biology. RECOMB 2003;131-7.
27. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68 (2001) 978-989
28. Tsuzuki T, Fujii Y, Sakumi K, et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA 1996;93:6236-40.
29. Sonoda E., Sasaki M.S., Buerstedde J.M., et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. Embo J 17 (1998) 598-608
30. Raderschall E., Stout K., Freier S., Suckow V., Schweiger S., and Haaf T. Elevated levels of Rad51 recombination protein in tumour cells. Cancer Res 62 (2002) 219-225
31. Flygare J., Falt S., Ottervald J., et al. Effects of HsRad51 overexpression on cell proliferation, cell cycle progression, and apoptosis. Exp Cell Res 268 (2001) 61-69
32. Xia S.J., Shammas M.A., and Shmookler Reis R.J. Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cel Biol 17 (1997) 7151-7158
33. Motulsky A.G. (1995) Jewish diseases and origins. Nat Genet 9 (1995) 99-101